Biosimilars have the potential to be considered comparable to generics and offer healthcare benefits...
Read moreNICE propose to charge to conduct single technology appraisals from May 2017.
Read moreEnabling physicians to identify patients who are most likely to respond to treatment thereby achievi...
Read morePharma companies must start preparing its NICE submission at the time of making the regulatory subm...
Read moreTopics include our perspectives on an EU commission report on how international reference pricing ca...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read moreThe aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreThe proposal states that the CDF should become a "managed access" fund for new cancer dugs, with cle...
Read moreNHS England have recently proposed that NICE should take a more direct role in determining which pro...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read more